Get the Stockscreener App
20.66
0.10%
0.02
After Hours:
20.71
0.05
+0.24%
Elanco Animal Health Inc stock is traded at $20.66, with a volume of 3.78M.
It is up +0.10% in the last 24 hours and up +12.10% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$20.64
Open:
$20.64
24h Volume:
3.78M
Relative Volume:
0.54
Market Cap:
$10.26B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
51.65
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
+5.35%
1M Performance:
+12.10%
6M Performance:
+125.79%
1Y Performance:
+40.93%
1-Day Range:
$20.41
$20.84
1-Week Range:
$19.46
$20.92
52-Week Range:
$8.02
$20.92
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
20.66 | 10.25B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
145.36 | 64.89B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.11B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.79 | 39.85B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.96 | 22.95B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
453.28 | 20.49B | 3.08B | 1.24B | 1.07B | 25.61 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Animal Health (ELAN): Assessing Valuation After Recent Share Price Momentum - simplywall.st
Visual analytics tools that track Elanco Animal Health Incorporated performanceJuly 2025 Earnings & Safe Capital Growth Tips - newser.com
Can Elanco Animal Health Incorporated rally from current levelsQuarterly Market Summary & AI Enhanced Execution Alerts - newser.com
Using economic indicators to assess Elanco Animal Health Incorporated potentialJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - newser.com
What catalysts could drive Elanco Animal Health Incorporated stock higherGold Moves & Safe Entry Zone Tips - newser.com
Elanco Animal Health Hits New 52-Week High of $20.91 - Markets Mojo
Elanco Animal Health (ELAN) Is Up 8.2% After FDA Strengthens Zenrelia Safety Labeling – Has the Bull Case Changed? - simplywall.st
Q&A with Elanco’s Jeff Simmons on blockbusters, challenges and growing up on a vineyard - Indianapolis Business Journal
After 5 years, Elanco moves in to west side Indy headquarters. Take a look inside - IndyStar
Is this a good reentry point in Elanco Animal Health IncorporatedInsider Buying & AI Based Buy/Sell Signal Reports - newser.com
Can Elanco Animal Health Incorporated stock attract ESG investmentsTrade Risk Assessment & Accurate Technical Buy Alerts - newser.com
Is Elanco Animal Health Incorporated stock a smart buy before Fed meetingTrade Risk Summary & Community Trade Idea Sharing - newser.com
How to build a dashboard for Elanco Animal Health Incorporated stockPortfolio Performance Report & High Accuracy Buy Signal Tips - newser.com
Sentiment analysis tools applied to Elanco Animal Health Incorporated2025 Retail Activity & Long-Term Growth Stock Strategies - newser.com
ASR Vermogensbeheer N.V. Trims Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health (NYSE:ELAN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Elanco Opens New $200 Million Global Headquarters in Downtown Indianapolis - Hoosier Ag Today
IEDC approves $10M in federal funding to launch Indianapolis venture studio - Inside INdiana Business
Elanco opens new headquarters, some anticipate era of health innovation in the state - WFYI
Elanco Animal Health Hits New 52-Week High at $20.19 - Markets Mojo
Ribbon cut on $200 million Elanco animal health campus - Fox 59
Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement - GuruFocus
Elanco Animal Health (ELAN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Why Elanco Animal Health Incorporated stock fits value portfolios2025 Investor Takeaways & Weekly High Return Stock Opportunities - newser.com
Elanco Animal Health Hits New 52-Week High at $19.70 - Markets Mojo
Why retail investors pile into Elanco Animal Health Incorporated stock2025 Stock Rankings & Daily Chart Pattern Signals - newser.com
Elanco Animal Health (ELAN): Valuation in Focus Following FDA-Backed Zenrelia Label Upgrade - simplywall.st
Elanco Animal Health Hits New 52-Week High at $19.27 - Markets Mojo
Elanco Animal Health stock reaches 52-week high at 19.36 USD - Investing.com Canada
Assessing Elanco Animal Health: Insights From 6 Financial Analysts - Benzinga
Elanco Animal Health (ELAN) Receives Price Target Boost from Sti - GuruFocus
Stifel Nicolaus Raises Elanco Animal Health (NYSE:ELAN) Price Target to $23.00 - MarketBeat
Why Elanco (ELAN) Stock Is Up Today - TradingView
BofA Securities Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Stifel Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Raises Target Price to $23 - 富途牛牛
Stifel raises Elanco Animal Health stock price target to $23 on strong product growth - Investing.com
Elanco Animal Health Hits New 52-Week High at $19.34 - Markets Mojo
Elanco Animal Health Incorporated (ELAN) Joins S&P MidCap 400 Following Strong Q2 Growth and Product Ramp-Up - Yahoo Finance
Elanco (ELAN) Advances with FDA Label Update for Zenrelia - GuruFocus
Elanco (ELAN) Updates Zenrelia Label Following FDA Review - GuruFocus
FDA Removes Key Safety Warning: Elanco's Zenrelia Pet Drug Shows Strong Safety Profile After 500K+ Dogs Treated - Stock Titan
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
4.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):